Pathologic response to preoperative chemotherapy: A new outcome end point after resection of hepatic colorectal metastases

Dan G. Blazer, Yoji Kishi, Dipen M. Maru, Scott Kopetz, Yun Shin Chun, Michael J. Overman, David Fogelman, Cathy Eng, David Z. Chang, Huamin Wang, Daria Zorzi, Dario Ribero, Lee M. Ellis, Katrina Y. Glover, Robert A. Wolff, Steven A. Curley, Eddie K. Abdalla, Jean Nicolas Vauthey

Research output: Contribution to journalArticle

433 Citations (Scopus)

Abstract

Purpose: The primary goal of this study was to evaluate whether pathologic response to chemotherapy predicts patient survival after preoperative chemotherapy and resection of colorectal liver metastases (CLM). The secondary goal of the study was to identify the clinical predictors of pathologic response. Patients and Methods: A retrospective review was performed of 305 patients who underwent preoperative irinotecan- or oxaliplatin-based chemotherapy, followed by resection of CLM. Pathologic response was systematically evaluated and reported as the mean of the percentage of cancer cells remaining within each tumor. Univariate and multivariate analyses were performed to identify the predictors of pathologic response and survival. Results: Cumulative 5-year overall survival rates by pathologic response status were as follows: 75% complete response (no residual cancer cells), 56% major response (1% to 49% residual cancer cells), and 33% minor response (≥ 50% residual cancer cells; complete v major response, P = .037; major v minor response, P = .028). Multivariate analysis revealed that only surgical margin status (P = .050; hazard ratio [HR], 1.77) and pathologic response (major response: P = .034; HR, 4.80; minor response: P = .007; HR, 6.93) were independent predictors of survival. Multivariate analysis of the predictors of pathologic response revealed that carcinoembryonic antigen level ≤ 5 ng/mL, tumor size ≤ 3 cm, and chemotherapy with fluoropyrimidine plus oxaliplatin and bevacizumab were independent predictors of pathologic response. Conclusion: Pathologic response predicts survival after preoperative chemotherapy and resection of CLM. Degree of pathologic response represents a new outcome end point for prognosis after resection of CLM.

Original languageEnglish
Pages (from-to)5344-5351
Number of pages8
JournalJournal of Clinical Oncology
Volume26
Issue number33
DOIs
Publication statusPublished - Nov 20 2008

Fingerprint

oxaliplatin
Neoplasm Metastasis
Residual Neoplasm
Drug Therapy
Liver
irinotecan
Survival
Multivariate Analysis
Neoplasms
Carcinoembryonic Antigen
Survival Rate

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Blazer, D. G., Kishi, Y., Maru, D. M., Kopetz, S., Chun, Y. S., Overman, M. J., ... Vauthey, J. N. (2008). Pathologic response to preoperative chemotherapy: A new outcome end point after resection of hepatic colorectal metastases. Journal of Clinical Oncology, 26(33), 5344-5351. https://doi.org/10.1200/JCO.2008.17.5299

Pathologic response to preoperative chemotherapy : A new outcome end point after resection of hepatic colorectal metastases. / Blazer, Dan G.; Kishi, Yoji; Maru, Dipen M.; Kopetz, Scott; Chun, Yun Shin; Overman, Michael J.; Fogelman, David; Eng, Cathy; Chang, David Z.; Wang, Huamin; Zorzi, Daria; Ribero, Dario; Ellis, Lee M.; Glover, Katrina Y.; Wolff, Robert A.; Curley, Steven A.; Abdalla, Eddie K.; Vauthey, Jean Nicolas.

In: Journal of Clinical Oncology, Vol. 26, No. 33, 20.11.2008, p. 5344-5351.

Research output: Contribution to journalArticle

Blazer, DG, Kishi, Y, Maru, DM, Kopetz, S, Chun, YS, Overman, MJ, Fogelman, D, Eng, C, Chang, DZ, Wang, H, Zorzi, D, Ribero, D, Ellis, LM, Glover, KY, Wolff, RA, Curley, SA, Abdalla, EK & Vauthey, JN 2008, 'Pathologic response to preoperative chemotherapy: A new outcome end point after resection of hepatic colorectal metastases', Journal of Clinical Oncology, vol. 26, no. 33, pp. 5344-5351. https://doi.org/10.1200/JCO.2008.17.5299
Blazer, Dan G. ; Kishi, Yoji ; Maru, Dipen M. ; Kopetz, Scott ; Chun, Yun Shin ; Overman, Michael J. ; Fogelman, David ; Eng, Cathy ; Chang, David Z. ; Wang, Huamin ; Zorzi, Daria ; Ribero, Dario ; Ellis, Lee M. ; Glover, Katrina Y. ; Wolff, Robert A. ; Curley, Steven A. ; Abdalla, Eddie K. ; Vauthey, Jean Nicolas. / Pathologic response to preoperative chemotherapy : A new outcome end point after resection of hepatic colorectal metastases. In: Journal of Clinical Oncology. 2008 ; Vol. 26, No. 33. pp. 5344-5351.
@article{a42d729e31b646c6923d85bda889670b,
title = "Pathologic response to preoperative chemotherapy: A new outcome end point after resection of hepatic colorectal metastases",
abstract = "Purpose: The primary goal of this study was to evaluate whether pathologic response to chemotherapy predicts patient survival after preoperative chemotherapy and resection of colorectal liver metastases (CLM). The secondary goal of the study was to identify the clinical predictors of pathologic response. Patients and Methods: A retrospective review was performed of 305 patients who underwent preoperative irinotecan- or oxaliplatin-based chemotherapy, followed by resection of CLM. Pathologic response was systematically evaluated and reported as the mean of the percentage of cancer cells remaining within each tumor. Univariate and multivariate analyses were performed to identify the predictors of pathologic response and survival. Results: Cumulative 5-year overall survival rates by pathologic response status were as follows: 75{\%} complete response (no residual cancer cells), 56{\%} major response (1{\%} to 49{\%} residual cancer cells), and 33{\%} minor response (≥ 50{\%} residual cancer cells; complete v major response, P = .037; major v minor response, P = .028). Multivariate analysis revealed that only surgical margin status (P = .050; hazard ratio [HR], 1.77) and pathologic response (major response: P = .034; HR, 4.80; minor response: P = .007; HR, 6.93) were independent predictors of survival. Multivariate analysis of the predictors of pathologic response revealed that carcinoembryonic antigen level ≤ 5 ng/mL, tumor size ≤ 3 cm, and chemotherapy with fluoropyrimidine plus oxaliplatin and bevacizumab were independent predictors of pathologic response. Conclusion: Pathologic response predicts survival after preoperative chemotherapy and resection of CLM. Degree of pathologic response represents a new outcome end point for prognosis after resection of CLM.",
author = "Blazer, {Dan G.} and Yoji Kishi and Maru, {Dipen M.} and Scott Kopetz and Chun, {Yun Shin} and Overman, {Michael J.} and David Fogelman and Cathy Eng and Chang, {David Z.} and Huamin Wang and Daria Zorzi and Dario Ribero and Ellis, {Lee M.} and Glover, {Katrina Y.} and Wolff, {Robert A.} and Curley, {Steven A.} and Abdalla, {Eddie K.} and Vauthey, {Jean Nicolas}",
year = "2008",
month = "11",
day = "20",
doi = "10.1200/JCO.2008.17.5299",
language = "English",
volume = "26",
pages = "5344--5351",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "33",

}

TY - JOUR

T1 - Pathologic response to preoperative chemotherapy

T2 - A new outcome end point after resection of hepatic colorectal metastases

AU - Blazer, Dan G.

AU - Kishi, Yoji

AU - Maru, Dipen M.

AU - Kopetz, Scott

AU - Chun, Yun Shin

AU - Overman, Michael J.

AU - Fogelman, David

AU - Eng, Cathy

AU - Chang, David Z.

AU - Wang, Huamin

AU - Zorzi, Daria

AU - Ribero, Dario

AU - Ellis, Lee M.

AU - Glover, Katrina Y.

AU - Wolff, Robert A.

AU - Curley, Steven A.

AU - Abdalla, Eddie K.

AU - Vauthey, Jean Nicolas

PY - 2008/11/20

Y1 - 2008/11/20

N2 - Purpose: The primary goal of this study was to evaluate whether pathologic response to chemotherapy predicts patient survival after preoperative chemotherapy and resection of colorectal liver metastases (CLM). The secondary goal of the study was to identify the clinical predictors of pathologic response. Patients and Methods: A retrospective review was performed of 305 patients who underwent preoperative irinotecan- or oxaliplatin-based chemotherapy, followed by resection of CLM. Pathologic response was systematically evaluated and reported as the mean of the percentage of cancer cells remaining within each tumor. Univariate and multivariate analyses were performed to identify the predictors of pathologic response and survival. Results: Cumulative 5-year overall survival rates by pathologic response status were as follows: 75% complete response (no residual cancer cells), 56% major response (1% to 49% residual cancer cells), and 33% minor response (≥ 50% residual cancer cells; complete v major response, P = .037; major v minor response, P = .028). Multivariate analysis revealed that only surgical margin status (P = .050; hazard ratio [HR], 1.77) and pathologic response (major response: P = .034; HR, 4.80; minor response: P = .007; HR, 6.93) were independent predictors of survival. Multivariate analysis of the predictors of pathologic response revealed that carcinoembryonic antigen level ≤ 5 ng/mL, tumor size ≤ 3 cm, and chemotherapy with fluoropyrimidine plus oxaliplatin and bevacizumab were independent predictors of pathologic response. Conclusion: Pathologic response predicts survival after preoperative chemotherapy and resection of CLM. Degree of pathologic response represents a new outcome end point for prognosis after resection of CLM.

AB - Purpose: The primary goal of this study was to evaluate whether pathologic response to chemotherapy predicts patient survival after preoperative chemotherapy and resection of colorectal liver metastases (CLM). The secondary goal of the study was to identify the clinical predictors of pathologic response. Patients and Methods: A retrospective review was performed of 305 patients who underwent preoperative irinotecan- or oxaliplatin-based chemotherapy, followed by resection of CLM. Pathologic response was systematically evaluated and reported as the mean of the percentage of cancer cells remaining within each tumor. Univariate and multivariate analyses were performed to identify the predictors of pathologic response and survival. Results: Cumulative 5-year overall survival rates by pathologic response status were as follows: 75% complete response (no residual cancer cells), 56% major response (1% to 49% residual cancer cells), and 33% minor response (≥ 50% residual cancer cells; complete v major response, P = .037; major v minor response, P = .028). Multivariate analysis revealed that only surgical margin status (P = .050; hazard ratio [HR], 1.77) and pathologic response (major response: P = .034; HR, 4.80; minor response: P = .007; HR, 6.93) were independent predictors of survival. Multivariate analysis of the predictors of pathologic response revealed that carcinoembryonic antigen level ≤ 5 ng/mL, tumor size ≤ 3 cm, and chemotherapy with fluoropyrimidine plus oxaliplatin and bevacizumab were independent predictors of pathologic response. Conclusion: Pathologic response predicts survival after preoperative chemotherapy and resection of CLM. Degree of pathologic response represents a new outcome end point for prognosis after resection of CLM.

UR - http://www.scopus.com/inward/record.url?scp=56749096759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56749096759&partnerID=8YFLogxK

U2 - 10.1200/JCO.2008.17.5299

DO - 10.1200/JCO.2008.17.5299

M3 - Article

C2 - 18936472

AN - SCOPUS:56749096759

VL - 26

SP - 5344

EP - 5351

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 33

ER -